Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galena Biopharma GALE

Healthcare Biotechnology
"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive... see more

Recent & Breaking News (NDAQ:GALE)

13F from Einhorn's Greenlight Shows Increased Stake in Dillard's

Press Releases February 16, 2016

Galena Biopharma Announces Proposed Settlement of Derivative Litigation

Press Releases February 16, 2016

Galena Biopharma Announces Notice of Allowance of U.S. Patent for NeuVax(TM) (nelipepimut-S)

GlobeNewswire February 8, 2016

Galena Biopharma to Present at the BIO CEO & Investor Conference

GlobeNewswire February 2, 2016

Galena Biopharma Presents Observational Study Data in Gastric Cancer Patients at the ASCO 2016 Gastrointestinal Cancers Symposium

GlobeNewswire January 21, 2016

Galena Biopharma Provides 2016 Outlook

GlobeNewswire January 13, 2016

Galena Biopharma to Present at NobleCon12 - Noble Financial Capital Markets' Twelfth Annual Investor Conference

GlobeNewswire January 11, 2016

Galena Biopharma Announces Pricing of Public Offering of Common Stock and Warrants

GlobeNewswire January 7, 2016

Galena Biopharma Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire January 6, 2016

Midatech Completes Acquisition of Zuplenz®

GlobeNewswire December 30, 2015

Market Influences That Drive Equities Forward - New Research on Galena Biopharma, XBiotech, KEMET and Control4

Accesswire December 24, 2015

Galena Biopharma Announces a Change to Its Board of Directors

GlobeNewswire December 24, 2015

Galena Biopharma to Sell Zuplenz® (ondansetron) Oral Soluble Film, Completing Divestiture of Commercial Operations

GlobeNewswire December 18, 2015

Midatech Agrees to Acquire Marketed Oncology Product, Zuplenz®, From Galena Biopharma, Inc.

GlobeNewswire December 18, 2015

Galena Biopharma Announces Departure of Chief Financial Officer

GlobeNewswire December 11, 2015

Galena Biopharma Presents Final GALE-401 Phase 2 Clinical Data at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire December 8, 2015

Galena Biopharma Announces Settlement of Securities Class Action and Shareholder Derivative Lawsuits

GlobeNewswire December 4, 2015

Galena Biopharma to Present at the Oppenheimer 26th Annual Healthcare Conference

GlobeNewswire November 30, 2015

Market Data on Movers and Shakers - Research on HomeTrust Bancshares, Liquidity Services, Galena Biopharma and Hovnanian Enterprises

Accesswire November 24, 2015

Galena Biopharma Completes Divestiture of Abstral(R) (fentanyl) Sublingual Tablets as Part of Strategic Focus on Its Immunotherapy Pipeline

GlobeNewswire November 20, 2015